Related Experiment Video
Updated: Jul 9, 2026
09:43
Multimodal Study of Murine Cardiovascular Remodeling: Four-Dimensional Ultrasound and Mass Spectrometry Imaging
Published on: January 10, 2025
Products--old, new, and emerging.
Vladimir W Spolsky1, Brian P Black, Larry Jenson
1Division of Public Health and Community Dentistry, University of California, Los Angeles, School of Dentistry, 90095-1668, USA.
Journal of the California Dental Association
|November 30, 2007
Summary
Understanding dental caries requires knowledge of available dental products for effective patient interventions. This review examines the evidence for current and emerging dental products to guide clinical recommendations.
Area of Science:
- Dentistry
- Cariology
- Dental Product Science
Background:
- Dental caries etiology, prevention, and treatment paradigms are evolving.
- Clinicians need evidence-based guidance on available dental products.
- Patient intervention recommendations require understanding current market offerings.
Purpose of the Study:
- To review the evidence base for existing dental products.
- To evaluate recently introduced dental products.
- To support clinicians in making informed patient care recommendations.
Main Methods:
- Literature review of scientific evidence.
- Analysis of current and emerging dental product data.
- Synthesis of findings on product efficacy and application.
Main Results:
- Evidence supporting various dental products for caries management is presented.
- Newer products and their potential benefits are discussed.
- Gaps in evidence for certain interventions may be highlighted.
Conclusions:
- An informed understanding of dental products is crucial for modern caries management.
- Evidence-based selection of dental products aids in effective patient care.
- This review provides a foundation for prudent clinical decision-making regarding dental interventions.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...